Why Korea?

South Korea is one of Asia’s most advanced pharmaceutical and digital health markets, and a global leader in biosimilars and AI‑driven innovation.

South Korea has rapidly emerged as a powerhouse in life sciences- pharmaceutical market valued at USD 21.8 billion in 2024, medical/ healthcare market valued at USD 200 Billion in 2024,

South Korea is know to consistently ranks as having one of the world's best healthcare systems. High adoption on advanced technologies in healthacare system allows South Korea to be 2nd globally in the 2025 CEOWORLD Health Care Index.

With the government prioritizing AI adoption in pharmaceuticals and healthcare, major Korean pharma/healthcare companies have already announced strategies to integrate AI into R&D pipelines and business portfolios, seeking for international companies with cutting-edge solutions towards innovation innovation.

Examples of the strong track record of South Korea in life science sector:

- MedImmune (AstraZeneca’s R&D arm, UK/Sweden) partnered with South Korea’s Alteogen in a $1.35B global licensing deal

- As of 2024–2025, South Korea ranks 6th globally in industry-sponsored clinical trials

-In 2025, 18 biosimilars were FDA approved, with 5 products from South Korean players